JP2015528454A5 - - Google Patents

Download PDF

Info

Publication number
JP2015528454A5
JP2015528454A5 JP2015529009A JP2015529009A JP2015528454A5 JP 2015528454 A5 JP2015528454 A5 JP 2015528454A5 JP 2015529009 A JP2015529009 A JP 2015529009A JP 2015529009 A JP2015529009 A JP 2015529009A JP 2015528454 A5 JP2015528454 A5 JP 2015528454A5
Authority
JP
Japan
Prior art keywords
vegf antagonist
medicament
administered
antibody
medicament according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015529009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015528454A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/067846 external-priority patent/WO2014033184A1/en
Publication of JP2015528454A publication Critical patent/JP2015528454A/ja
Publication of JP2015528454A5 publication Critical patent/JP2015528454A5/ja
Pending legal-status Critical Current

Links

JP2015529009A 2012-08-28 2013-08-28 眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用 Pending JP2015528454A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261693913P 2012-08-28 2012-08-28
US61/693,913 2012-08-28
PCT/EP2013/067846 WO2014033184A1 (en) 2012-08-28 2013-08-28 Use of a vegf antagonist in treating ocular vascular proliferative diseases

Publications (2)

Publication Number Publication Date
JP2015528454A JP2015528454A (ja) 2015-09-28
JP2015528454A5 true JP2015528454A5 (enExample) 2016-11-24

Family

ID=49083670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015529009A Pending JP2015528454A (ja) 2012-08-28 2013-08-28 眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用

Country Status (4)

Country Link
US (1) US20150297675A1 (enExample)
EP (1) EP2890389A1 (enExample)
JP (1) JP2015528454A (enExample)
WO (1) WO2014033184A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
US20160130321A1 (en) * 2013-06-20 2016-05-12 Gabriela Burian Use of a vegf antagonist in treating macular edema
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
TWI799366B (zh) * 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
US20180326126A1 (en) * 2015-11-18 2018-11-15 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
US10973867B2 (en) 2015-12-30 2021-04-13 Marshall University Research Corporation Compositions and methods for treating retinopathy
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
EP3407868A1 (en) 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
MY202872A (en) * 2017-11-20 2024-05-28 Just Evotec Biologics Inc Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
MX2020009140A (es) * 2018-03-16 2020-09-28 Novartis Ag Metodos para el tratamiento de enfermedades oculares.
KR102038008B1 (ko) * 2018-04-03 2019-10-29 주식회사 루트로닉 안과용 치료장치 및 이의 제어방법
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
WO2021051003A1 (en) * 2019-09-13 2021-03-18 Aldeyra Therapeutics, Inc. Ophthalmic formulations of methotrexate
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
BR112022025227A2 (pt) 2020-06-11 2023-01-03 Genentech Inc Conjugados, composição farmacêutica, formulação líquida, métodos para preparar um conjugado, para aumentar a estabilidade, para tratar um indivíduo, para entregar um polipeptídeo de ligação, para entregar um peptídeo curto, para entregar um agente biologicamente ativo, método para reduzir a conjugação lipídio-proteína-esqueleto e método para aumentar a atividade biológica, uso do conjugado e sistema ou kit
US20240353426A1 (en) * 2021-08-13 2024-10-24 The Board Of Trustees Of The Leland Stanford Junior University Methods for Diagnosing and Treating Ischemic Eye Disease
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
US11911385B1 (en) 2022-12-14 2024-02-27 Aldeyra Therapeutics, Inc. Methotrexate treatment methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060122374A1 (en) * 2002-02-07 2006-06-08 Peter Mertins Albumin-fused anti-angiogenesis peptides
US7399612B2 (en) * 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US11078262B2 (en) * 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
WO2010005527A1 (en) * 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
NZ592591A (en) * 2008-11-03 2012-04-27 Molecular Partners Ag Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction
EA201190273A1 (ru) * 2009-05-28 2012-12-28 Глаксо Груп Лимитед Комбинация антагониста tnf-альфа и антагониста vegf для применения в лечении или предупреждении заболеваний глаз
WO2012105610A1 (ja) * 2011-02-02 2012-08-09 公立大学法人名古屋市立大学 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬

Similar Documents

Publication Publication Date Title
JP2012525415A5 (enExample)
KR102373289B1 (ko) 지속성 부종을 갖는 삼출성 노인성 황반변성을 치료하기 위한 시롤리무스의 용도
JP2016528202A5 (enExample)
US11478465B2 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
JP2012072152A5 (enExample)
WO2014033184A1 (en) Use of a vegf antagonist in treating ocular vascular proliferative diseases
JP2014532072A5 (enExample)
ME00591B (me) Upotreba dii4 antagonista kod ishemijske povrede ili vaskularne insuficijencije
JP2017537105A5 (enExample)
JP2019510078A5 (enExample)
Tomomatsu et al. Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions
CN114306575A (zh) 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
JP2017525769A5 (enExample)
JP2012505162A5 (enExample)
JP5557408B1 (ja) 眼底疾患治療剤
Fang et al. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema
PH12020551015A1 (en) Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
JP2016516761A5 (enExample)
US20170224815A1 (en) Method of Preventing and Treating Retinal Microvasculature Inflammation Using C-Met Signaling Pathway Inhibition
KR20160013026A (ko) 폴립양 맥락막 혈관병증의 치료
Khan et al. Interferon associated retinopathy
SHARM et al. Clinical Utilisation of Bevacizumab and Patient Monitoring in Retinal Vein Occlusion and Diabetic Macular Edema
Tataru et al. Evaluation of the efficacy and safety of intravitreal bevacizumab for macular edema related to retinal vein occlusion
CN104703606A (zh) 1-金刚烷乙氧基-3-吗啉基-2-丙醇或其药学上可接受的盐在药物组合物中作为视神经网膜保护物使用
Mahar et al. Visual Outcome Following Intra-vitreal Bevacizumab Injection in Neovascular Age-related Macular Degeneration